The new American guidelines: Critical analysis;Nouvelles recommandations américaines: Analyse critique

American Journal of Cardiovascular Drugs

Volumn 4, Issue SPEC. ISS. 1, 2004, Pages 7-11

  Kaplan, Norman M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; PERINDOPRIL; THIAZIDE DIURETIC AGENT;

BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; DISEASE CLASSIFICATION; HEALTH BEHAVIOR; HEART FAILURE; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; MOTIVATION; OBESITY; PATIENT CARE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

EID: 4544321821     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200404991-00005     Document Type: Review

References (26)

1. Chobanian AV, Bakris GL, Black HR, et al. for the Joint National Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC-7 Report. JAMA 2003; 289: 2560-72
2. Joint National Committee. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-46
3. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension. 2004; 43: 10-7
4. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289: 2363-9
5. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002; 360: 1903-13
6. Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, et al. Health-related quality of life of subjects with known and unknown hypertension: Results from the population-based Hortega study. J Hypertens 2003; 21: 1283-9
7. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-10
8. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 2002; 2888: 1882-8
9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97
10. Kaplan NM. "Treatment of Hypertension: Drug Therapy." Chapter 7 in Kaplan's Clinical Hypertension, 8th ed. Philadelphia: Lippincott Williams & Wilkins. 2002. pp 309-312
11. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapics used as first-line agents: A network meta-analysis. JAMA 2003; 289: 2534-44
12. Kuo S-W, Dee P, Hung Y-J, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens 2003; 16: 623-8
13. Bakris GL, Williams M, Dworkin L, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes. Am J Kidney Dis 2000; 36: 646-61
14. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393-404
15. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35: 539-43
16. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62
17. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36). Br Med J 2000; 321: 412-9
18. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 2003; 139: 244-52
19. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants in the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218-25
20. Wright JT Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihyper-tensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288: 2421-31
21. Mulrow CD, Townsend RR. Guiding lights for antihypertensive treatment in patients with nondiabetic chronic renal disease: Proteinuria and blood pressure levels? Ann Intern Med 2003; 139: 296-8
22. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-66
23. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53
24. The EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (The EUROPA study). Lancet 2003; 362: 782-8
25. Sachs FM, Svetkey LP, Vollmer WM, et al., for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10
26. Trichopoulou A, Costacou T, Bamia C, et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348: 2599-608